Translate


Thursday, November 24, 2011

Claire McCaskill Asks for Probe of Obama Donor Contract

Hat tip Daily Caller



Ron Perelman
Well-connected Democrat

Kudos to Senator Claire McCaskill (D-MO) for wanting to get answers about a suspicious contract  awarded to a company run by a Democrat donor.

http://dailycaller.com/2011/11/24/mccaskill-asks-for-investigation-into-obama-administrations-sole-source-vaccine-contract/

And who is Ron Perelman, you ask?

http://en.wikipedia.org/wiki/Ronald_Perelman

Relax, folks. It's only $433 million. And this firm was the only one asked to submit a bid? That stinks right there.

Do you think any of those Occupy protesters who hate capitalism so much will pick up on this issue?

Sorry I asked.

2 comments:

Miggie said...

Two facets that surprise me here. First that a Democrat asked for the investigation. Second, the vaccination is for a disease that has been eradicated! I got this info from a Google search on the history of Small pox.
"In 1967 the World Health Organization (WHO) started a worldwide campaign to eradicate smallpox. This goal was accomplished in 10 years due in a large part to massive vaccination efforts. The last endemic case of smallpox occurred in Somalia in 1977. On May 8, 1980, the World Health Assembly declared the world free of smallpox.

The United States stopped vaccinating the general population in 1972, but continued to vaccinate military personnel. It was recommended that vaccination of military personnel stop in 1986, and vaccination was officially stopped in military recruits in 1990."

All that money for nothing! To a Democratic big wig! In a no-bid deal!

Outrageous!

The election can't come soon enough! Let the electorate decide if we want more of the same.

Siarlys Jenkins said...

If Claire McCaskill called for an investigation, there may be good cause. But receiving only one bid for a vaccine contract MAY be the result of the well established trend that major pharma companies simply don't want to take on vaccine contracts -- the big money is in new drugs that they can charge a huge "R&D recovery" monopolistic 90% markup for.